FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients

N.S. Fracchiolla, S. Artuso, A. Cortelezzi, A.M. Pelizzari, P. Tozzi, M. Bonfichi, F. Bocchio, L. Gargantini, E. De Rosa, G.D. Vighi, L. Prestini, S. Sammassimo, N. Frungillo, M.C. Pasquini, A. Ragazzi, D. Boghi, A. Pastore, E. Lanzi, G. Gritti, G. QuaresminiS. Voltolini, R. Gaiardoni, C. Corti, M.C. Vilardo, M.L. La Targia, G. Berini, M. Magagnoli, C. Bacci, D. Consonni, A.L. Rivolta, G. Muti

Research output: Contribution to journalArticlepeer-review

Abstract

Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project “FarmaREL” has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring in haematological patients were collected electronically and then analysed with multiple logistic regression. Between January 2009 and December 2011, 887 reports were collected. The number of ADRs was higher in older adults (528; 59%), in male (490; 55%), and in non-Hodgkin lymphoma patients (343; 39%). Most reactions were severe (45% required or prolonged hospitalization), but in most cases, they were fully resolved at the time of reporting. According to Schumock and Thornton criteria, a percentage of ADRs as high as 7% was found to be preventable versus 2% according to reporter opinion. Patients' haematological diagnosis, not age or gender, resulted to be the variable that most influenced ADR, in particular severity and outcome. The employment of personnel specifically dedicated to pharmacovigilance is a successful strategy to improve the number and quality of ADR reports. “FarmaREL”, the first programme of active pharmacovigilance in oncohaematologic patients, significantly contributed to reach the WHO “Gold Standard” for pharmacovigilance in Lombardy, Italy. Copyright © 2017 John Wiley & Sons, Ltd.
Original languageEnglish
Pages (from-to)299-306
Number of pages8
JournalHematological Oncology
Volume36
Issue number1
DOIs
Publication statusPublished - 2018

Keywords

  • adverse drug reactions
  • drug safety
  • medication safety
  • patient safety
  • pharmacovigilance
  • alemtuzumab
  • allopurinol
  • amphotericin B
  • bleomycin
  • cisplatin
  • cotrimoxazole
  • cyclophosphamide
  • dexamethasone
  • doxorubicin
  • drug
  • etoposide
  • fludarabine
  • hydroxyurea
  • imatinib
  • lenalidomide
  • methotrexate
  • methylprednisolone
  • nilotinib
  • pegfilgrastim
  • phenytoin
  • prednisone
  • procarbazine
  • retinoic acid
  • rituximab
  • thalidomide
  • unindexed drug
  • vinblastine
  • vincristine
  • vinorelbine tartrate
  • zoledronic acid
  • abdominal pain
  • acute leukemia
  • adult
  • adverse drug reaction
  • aged
  • algorithm
  • anemia
  • Article
  • asthenia
  • cancer patient
  • cerebrovascular accident
  • chronic leukemia
  • dermatitis
  • diarrhea
  • digestive system perforation
  • drug eruption
  • drug substitution
  • drug surveillance program
  • drug treatment failure
  • drug withdrawal
  • edema
  • erythema
  • evaluation research
  • faintness
  • febrile neutropenia
  • female
  • fever
  • gastrointestinal hemorrhage
  • gastrointestinal infection
  • hematologic disease
  • Hodgkin disease
  • hospitalization
  • human
  • hyperhidrosis
  • inflammation
  • infusion related reaction
  • intestine infarction
  • Italy
  • laboratory test
  • leukopenia
  • major clinical study
  • malaise
  • male
  • middle aged
  • motor dysfunction
  • multiple myeloma
  • myelodysplastic syndrome
  • nausea
  • neuropathy
  • neutropenia
  • nonhodgkin lymphoma
  • pain
  • pancytopenia
  • patient monitoring
  • priority journal
  • pruritus
  • respiratory tract infection
  • sepsis
  • septic shock
  • sex ratio
  • skin exfoliation
  • stomatitis
  • thorax pain
  • thrombocytopenia
  • tremor
  • urticaria
  • virus infection
  • vomiting
  • complication
  • psychology
  • quality of life
  • Aged
  • Drug-Related Side Effects and Adverse Reactions
  • Female
  • Hematologic Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Pharmacovigilance
  • Quality of Life

Fingerprint Dive into the research topics of 'FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients'. Together they form a unique fingerprint.

Cite this